Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Literature DB >> 19907920

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Abstract

The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.

Entities: Disease

Mesh：

Substances：

Year: 2009 PMID： 19907920 DOI： 10.1007/s00018-009-0189-x

Source DB: PubMed Journal: Cell Mol Life Sci ISSN： 1420-682X Impact factor: 9.261

93 in total

1. RhoE binds to ROCK I and inhibits downstream signaling.

Authors: Kirsi Riento; Rosa M Guasch; Ritu Garg; Boquan Jin; Anne J Ridley
Journal: Mol Cell Biol Date: 2003-06 Impact factor: 4.272

2. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.

Authors: O Nakagawa; K Fujisawa; T Ishizaki; Y Saito; K Nakao; S Narumiya
Journal: FEBS Lett Date: 1996-08-26 Impact factor: 4.124

3. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

Authors: K Chitaley; C J Wingard; R Clinton Webb; H Branam; V S Stopper; R W Lewis; T M Mills
Journal: Nat Med Date: 2001-01 Impact factor: 53.440

4. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis.

Authors: Ying-Min Zhang; Jacqueline Bo; George E Taffet; Jiang Chang; Jianjian Shi; Anilkumar K Reddy; Lloyd H Michael; Michael D Schneider; Mark L Entman; Robert J Schwartz; Lei Wei
Journal: FASEB J Date: 2006-05 Impact factor: 5.191

5. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

Authors: Yuichi Kikuchi; Muneharu Yamada; Toshihiko Imakiire; Taketoshi Kushiyama; Keishi Higashi; Naomi Hyodo; Kojiro Yamamoto; Takashi Oda; Shigenobu Suzuki; Soichiro Miura
Journal: J Endocrinol Date: 2007-03 Impact factor: 4.286

6. Rho kinase inhibition enhances axonal regeneration in the injured CNS.

Authors: Alyson E Fournier; Bayan T Takizawa; Stephen M Strittmatter
Journal: J Neurosci Date: 2003-02-15 Impact factor: 6.167

7. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.

Authors: E Hampton Sessions; Yan Yin; Thomas D Bannister; Amiee Weiser; Evelyn Griffin; Jennifer Pocas; Michael D Cameron; Claudia Ruiz; Li Lin; Stephan C Schürer; Thomas Schröter; Philip LoGrasso; Yangbo Feng
Journal: Bioorg Med Chem Lett Date: 2008-10-25 Impact factor: 2.823

8. Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats.

Authors: H Tanaka; T Yamashita; K Yachi; T Fujiwara; H Yoshikawa; M Tohyama
Journal: Neuroscience Date: 2004 Impact factor: 3.590

9. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors: Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal: Diabetes Date: 2007-12-14 Impact factor: 9.461

10. Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure.

Authors: David Komander; Ritu Garg; Paul T C Wan; Anne J Ridley; David Barford
Journal: EMBO J Date: 2008-10-23 Impact factor: 11.598

62 in total

Review 1. Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors: Rebecca K Donegan; Raquel L Lieberman
Journal: J Med Chem Date: 2015-09-25 Impact factor: 7.446

2. Autophagy negatively regulates early axon growth in cortical neurons.

Authors: Byung-Kwan Ban; Mi-Hee Jun; Hyun-Hee Ryu; Deok-Jin Jang; S Tariq Ahmad; Jin-A Lee
Journal: Mol Cell Biol Date: 2013-08-05 Impact factor: 4.272

Review 3. Rho-kinase: regulation, (dys)function, and inhibition.

Authors: Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian
Journal: Biol Chem Date: 2013-11 Impact factor: 3.915

Review 4. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors: Jianjian Shi; Lei Wei
Journal: J Cardiovasc Pharmacol Date: 2013-10 Impact factor: 3.105

5. p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility.

Authors: Ko Momotani; Mykhaylo V Artamonov; Darkhan Utepbergenov; Urszula Derewenda; Zygmunt S Derewenda; Avril V Somlyo
Journal: Circ Res Date: 2011-09-01 Impact factor: 17.367

6. Rho-associated kinase is a therapeutic target in neuroblastoma.

Authors: Cecilia Dyberg; Susanne Fransson; Teodora Andonova; Baldur Sveinbjörnsson; Jessika Lännerholm-Palm; Thale K Olsen; David Forsberg; Eric Herlenius; Tommy Martinsson; Bertha Brodin; Per Kogner; John Inge Johnsen; Malin Wickström
Journal: Proc Natl Acad Sci U S A Date: 2017-07-24 Impact factor: 11.205

7. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.

Authors: Chunhua Liu; Xuefei Shi; Li Wang; Ying Wu; Feiyan Jin; Cuiqing Bai; Yong Song
Journal: Tumour Biol Date: 2014-03-15

8. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Authors: Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins
Journal: Inflamm Bowel Dis Date: 2014-01 Impact factor: 5.325

9. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.

Authors: Sree Rayavarapu; Jack H Van der Meulen; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju; Susan M Knoblach
Journal: PLoS One Date: 2010-09-24 Impact factor: 3.240

10. Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma.

Authors: Junbo Zhang; Xue He; Yueying Ma; Yanli Liu; Huaiyin Shi; Weiwei Guo; Liangfa Liu
Journal: Int J Clin Exp Pathol Date: 2015-01-01